SAN DIEGO, March 2, 2016 /PRNewswire/ -- Shareholder Rights
Law Firm Johnson & Weaver, LLP is investigating potential
claims against Rockwell Medical, Inc., AAC Holdings, Inc., Dr.
Reddy's Laboratories Ltd. and Biota Pharmaceuticals, Inc, as
detailed below:
Rockwell Medical, Inc.
Johnson & Weaver, LLP is investigating potential violations
of the federal securities laws by Rockwell Medical, Inc.
(NASDAQ: RMTI) and certain of its officers and directors. On
September 9, 2015, Rockwell Medical
disclosed the U.S. commercial launch of Triferic, a FDA approved
iron product designed to replace iron and preserve hemoglobin in
hemodialysis patients in the United
States. On February 29, 2016,
Rockwell Medical's CFO Tom Klema
revealed to investors on a conference call that sales of Triferic
were "immaterial" for 2015; and in response analysts questioned the
Company's commercial viability in the dialysis arena.
If you have information that could assist in this
investigation, or if you are a Rockwell Medical shareholder and are
interested in learning more about the investigation or your legal
rights and remedies, please contact Jim
Baker (jimb@johnsonandweaver.com) by email or by phone
at 619-814-4471. If emailing, please include a phone number where
you can be reached.
AAC Holdings, Inc.
Johnson & Weaver, LLP has commenced an investigation of
possible claims against the Board of Directors of AAC Holdings,
Inc. (NYSE:AAC). The investigation arises from the indictment
of AAC's CEO and certain other employees on murder charges relating
to the death of an AAC patient in 2010.
If you are a long-term AAC shareholder and are interested in
learning more about the investigation or your legal rights and
remedies, please contact Jim Baker
(jimb@johnsonandweaver.com) by email or by phone
at 619-814-4471. If emailing, please include a phone number
where you can be reached.
Dr. Reddy's Laboratories Ltd.
Johnson & Weaver, LLP is investigating potential violations
of the federal securities laws by Dr. Reddy's Laboratories
Ltd. (NYSE: RDY) and certain of its officers. On November 5, 2015, the Director of the FDA's
Center for Drug Evaluation and Research sent a Warning Letter to
Dr. Reddy's relating to inadequate quality controls at three key
Indian facilities manufacturing raw pharmaceutical materials and
oncology medicines. The FDA stated that Dr. Reddy's may not receive
U.S. approvals for any new applications or supplements listing Dr.
Reddy's as a drug product or API manufacturer, and that FDA may
refuse admission into the U.S. of drugs manufactured at these three
plants until the problems were fixed.
If you are a Dr. Reddy's shareholder and are interested in
learning more about the investigation or your legal rights and
remedies, please contact Jim Baker
(jimb@johnsonandweaver.com) by email or by phone
at 619-814-4471. If emailing, please include a phone number where
you can be reached.
Biota Pharmaceuticals, Inc.
Johnson & Weaver, LLP is investigating whether certain
officers and directors of Biota Pharmaceuticals, Inc.,
(NASDAQ: BOTA) violated state or federal laws. On August 1, 2014 Biota announced its experimental
influenza drug failed to meet the main goal in a mid-stage study.
In April 2014 the U.S. Department of
Health and Human Services pulled out of a contract to support the
drug's development. The contract provided up to $231 million in financial support for the
development of laninamivir octanoate for the treatment of influenza
A and B in the United States.
If you have information that could assist in this
investigation, including former employees and others, or if you are
a Biota shareholder and are interested in learning more about the
investigation or your legal rights and remedies, please contact
Jim Baker
(jimb@johnsonandweaver.com) by email or by phone
at 619-814-4471. If emailing, please include a phone number
where you can be reached.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder
rights law firm with offices in California, New
York and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
http://www.johnsonandweaver.com. Attorney advertising. Past results
do not guarantee future outcomes.
Contact:
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
jimb@johnsonandweaver.com
Logo - http://photos.prnewswire.com/prnh/20160211/332409LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-rights-law-firm-johnson--weaver-llp-initiates-investigations-of-rockwell-medical-inc-aac-holdings-inc-dr-reddys-laboratories-ltd-and-biota-pharmaceuticals-inc-encourages-investors-to-contact-the-firm-for--300229457.html
SOURCE Johnson & Weaver, LLP